Aandelen in “Diensten aan de gezondheidssector”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Diensten aan de gezondheidssector”

17/02 · Labcorp Announces 2025 Fourth Quarter and Full Year Results · Persbericht

17/02 · Labcorp Announces 2025 Fourth Quarter and Full Year Results · Persbericht

11/02 · Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care · Persbericht

10/02 · Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share · Persbericht

10/02 · Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization · Persbericht

9/02 · Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors · Persbericht

5/02 · Strong commercial performance in 2025: Annual Recurring Revenue (ARR) of €108.0m (+8.8% as reported on 31 December 2025) and full-year revenue of €236.5m (+9.1% as reported) · Persbericht

2/02 · Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease · Persbericht

22/01 · Promethean named 'Company of the Year' at BETT Awards 2026 · Persbericht

21/01 · Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year · Persbericht

20/01 · Promethean ActivSuite Expands Compatibility with ChromeOS Integration · Persbericht

15/01 · Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026 · Persbericht

15/01 · Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect · Persbericht

14/01 · Labcorp Declares Quarterly Dividend · Persbericht

13/01 · Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk · Persbericht

12/01 · Promethean Exhibits at Major Global Trade Shows in Early 2026 · Persbericht

8/01 · Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026 · Persbericht

8/01 · NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp · Persbericht

6/01 · Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium · Persbericht

5/01 · Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan · Persbericht

5/01 · EQUASENS ACCELERATES ITS DIGITAL TRAINING STRATEGY FOR HEALTHCARE PROFESSIONALS WITH THE ACQUISITION OF EREVO, A LEADING PURE-PLAY E-LEARNING PROVIDER · Persbericht

Mijn selecties